Recombinant Human Growth Hormone

  title={Recombinant Human Growth Hormone},
  author={Stefano Benedini and Ileana Terruzzi and Adriano Lazzarin and Livio Luzi},
The role of hormonal and metabolic alterations in HIV-associated lipodystrophy syndrome is not yet clear. In patients with HIV-1 undergoing antiretroviral treatment, lipodystrophy is associated with peripheral fat wasting and central adiposity, dyslipidemia, insulin resistance, and increased intramuscular fat accumulation.In HIV lipodystrophy, changes in fat distribution are heterogeneous and can include reduced subcutaneous fat as well as increased visceral fat. In the literature, there is… 

Antropometry in HIV Patients: Effects of Recombinant Human Growth Hormone

The anthropometry of lipodystrophy in HIV patients and the indication of rhGH treatment in HIV-related lipody Strophy is discussed, which can be a useful treatment to diminish excess visceral fat.

Tesamorelin for the treatment of excess abdominal fat in HIV-infected individuals with lipodystrophy

A range of host and lifestyle factors, as well as antiretroviral drug choice, were associated with increased visceral adiposity, and management approaches included treatment switching.

Growth hormone and HIV infection: contribution to disease manifestations and clinical implications.

  • J. Falutz
  • Medicine, Biology
    Best practice & research. Clinical endocrinology & metabolism
  • 2011

Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.

Current evidence suggests that tesamorelin may be useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy, thereby potentially improving self image.

Population Pharmacokinetic Analysis of Tesamorelin in HIV-Infected Patients and Healthy Subjects

An open one-compartment model with first and zero order absorption processes and linear elimination is suitable to characterize the pharmacokinetics of tesamorelin in HIV-infected patients and healthy subjects.

Tesamorelin: A Growth Hormone-Releasing Factor Analogue for HIV-Associated Lipodystrophy

Tesamorelin is effective in improving visceral adiposity and body image in patients with HIV-associated lipodystrophy over 26-52 weeks of treatment and potential limitations for its use include high cost and lack of long-term safety and adherence data.

Recombinant Human Growth Hormone: HIV-Related Lipodystrophy

This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario.

HIV Infection and Lipodystrophy



Preferential loss of omental-mesenteric fat during growth hormone therapy of HIV-associated lipodystrophy.

There is preferential loss and regain of OMAT, compared with RPAT, in subjects with HIV-associated lipodystrophy undergoing growth hormone treatment, as it does in non-HIV-related conditions.

GH treatment reduces trunkal adiposity in HIV-infected patients with lipodystrophy: a randomized placebo-controlled study.

Low-dose GH administration is an effective treatment in reducing trunk obesity in HIV-infected patients with lipodystrophy.

Physiologic growth hormone replacement improves fasting lipid kinetics in patients with HIV lipodystrophy syndrome.

Physiologic GH replacement has salutary effects on abnormal lipid kinetics in HLS, mediated by diminished lipolysis and hepatic reesterification rather than by increased fat oxidation.

Intramyocellular lipid accumulation and reduced whole body lipid oxidation in HIV lipodystrophy.

Lipodystrophy in HIV-1 patients in antiretroviral treatment is associated with intramuscular fat accumulation, which may mediate the development of the insulin resistance syndrome.

Effects of growth hormone-releasing hormone on bone turnover in human immunodeficiency virus-infected men with fat accumulation.

GHRH improves fat distribution and bone metabolism in men with HIV-related fat accumulation and stimulatory effects of GHRH on bone turnover will translate into increased bone density in this population of men.

Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy.

Pulse analysis demonstrated decreased baseline GH in the LIPO subjects but no significant difference in pulse frequency and insulin-like growth factor-I was not different between the groups and the mean GH concentration was correlated inversely with mean GH concentrations in the HIV-infected patients.

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

Body composition, body fat distribution and insulin secretion in patients taking nucleoside reverse transcriptase inhibitor (NRTI) therapy in HIV-infected patients and five out of 12 patients had a major or mild improvement in their lipodystrophy after stavudine was discontinued.

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance is a common complication of HIV protease inhibitors and diabetes mellitus is relatively uncommon.

Growth hormone treatment of abdominally obese men reduces abdominal fat mass, improves glucose and lipoprotein metabolism, and reduces diastolic blood pressure.

It is demonstrated that GH can favorably affect some of the multiple perturbations associated with abdominal/visceral obesity, an improved insulin sensitivity, and favorable effects on lipoprotein metabolism and diastolic blood pressure.

Growth hormone (GH) responses to GH-releasing hormone-arginine testing in human immunodeficiency virus lipodystrophy.

Increased failure rates to standardized stimulation testing with GHRH-arginine are demonstrated in LIPO patients, in association with increased visceral adiposity, and the effects of low-dose GH should be assessed.